WEQUAL
8.11.2021 23:24:12 CET | Business Wire | Press release
Twenty-four women executives have been recognised by the WeQual Awards for their outstanding contribution to business from some of the biggest companies in the Europe, Middle East and Africa region. WeQual’s mission is to tackle the slow progress in appointing women to executive positions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211108006143/en/
Since its creation, more than 35% of the winners of previous WeQual Awards in the UK, EMEA, APAC and The Americas have already been promoted to the executive committees of major global companies.
The 24 WeQuals, all one level below Group ExCo or Group C-Suite leader, automatically become members of the WeQual Club. They join the 144 senior executives already enrolled. The winners in each category will be announced in January 2022.
The 24 WeQual Finalists for EMEA 2021:
Technology Category
- Cecile Bartenieff, COO of Global Banking & Investors Solutions and Global Head of Technology & Operations, Société Générale.
- Patricia Beau, Chief Technology Officer Lead / Partner For Consumer Healthcare, Sanofi.
- Miruna Senciuc, CEO, Romanian Branch, BNP Paribas Personal Finance.
Brand Category
- Mia Claselius, Vice President, Head of Communications, ABB Electrification, ABB Ltd.
- Noémie Ellezam, Group Chief Digital Strategy Officer, Société Générale.
- Anjana Srinivasan, Chief Operating Officer – HSBC Global Marketing, HSBC Holdings plc.
Transformation Category
- Naina Bhattacharya, Chief Information Security Officer, Danone.
- Christiane Lindenschmidt, Chief Digital and Data Officer, Markets and Securities Services, HSBC Holdings Plc.
- Chafika Chettaoui, Group Chief Data Officer, Suez.
Commercial Category
- Anne O'Leary, Chief Executive Officer, Vodafone Ireland, Vodafone Group Plc.
- Filipa Martins, Managing Director/CEO, Portugal, Edenred.
- Mieke De Schepper, Executive Vice President and Managing Director, Asia-Pacific, Amadeus IT Group.
Finance Category
- Anna Dimitrova, Chief Financial Officer and Strategy Director of Vodafone Germany
- Daria Dodonova, Chief Financial Officer, Magyar Telekom, Deutsche Telekom.
- Camila Japur, CFO Emerging Businesses, Ericsson.
Business Development Category
- Arancha Cordero, Chief Growth Officer Waters, Danone.
- Susan Uthayakumar, President, Sustainability Business Division, Schneider Electric.
- Bettina Möckel, Vice President Corporate Business Development, QIAGEN.
Procurement & Supply Chain Category
- Sigrid Brendel, Head of Global Procurement, CPO, Campari Group.
- Jessica Nordlinder, Chief Procurement Officer, Essity.
- Francesca Gamboni, Senior Vice President Global Supply Chain Groupe Stellantis, Stellantis.
People & Culture Category
- Audra Jenkins, Chief Diversity & Inclusion Officer, Randstad North America.
- Cecilia Hallengren, Senior Vice President, People and Culture, Volvo Group Trucks Technology, Volvo Group.
- Tina Mylon, SVP, Talent and Diversity, Schneider Electric.
Notes
Quotes available on request.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108006143/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom